Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The long-term safety picture, including the cardiovascular outcomes data from the SELECT trial (20% reduction in major cardiovascular events in patients with obesity and established CVD), is established
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed to manage type 2 diabetes and, more recently, approved for chronic weight management
Rights and permissions About this article Cite this article Starling, S
While injection site reactions occurred in 1.4% to 2.4% of clinical trial participants, mild bruising may be more frequent in real-world practice
The semaglutide group reduced 14.9% from their baseline body weight compared to 2.4% with the placebo group
CagriSema combines semaglutide with cagrilintide (an amylin analogue), targeting appetite through GLP-1R and amylin receptor pathways
